Photoselective vaporization of the prostate: outcome according to the prostate size in a series of 102 Japanese patients.
To identify the efficacy and safety of photoselective vaporization of the prostate (PVP) in relation to the prostate size in subjects with benign prostatic enlargement. The prospective study included 102 Japanese patients who underwent PVP. The efficacy and morbidity following PVP were compared in groups classified according to the baseline prostate size: prostates <40 cm(3) (group 1, n = 25), 40 cm(3) < or = prostates < 80 cm(3) (group 2, n = 53), and 80 cm(3) < or = prostates (group 3, n = 24). Each subgroup was assessed for the treatment efficacy in terms of peak urinary flow rate, post-void residual urine volume, International Prostate Symptom Score, and quality-of-life score at 3, 6 and 12 months after PVP. Except for a difference in International Prostate Symptom Score (group 2 vs 3) and peak urinary flow rate (groups 1 vs 3) at 6 months after PVP, no significant differences were observed among the groups in the level of improvement in each outcome variable. The efficacy of vaporization was significantly lower in group 1 (P < 0.05, group 1 vs 2 or 3). The hemoglobin loss after PVP did not differ substantially among the groups. No statistically significant difference was found among the three groups regarding the total incidence of adverse events. PVP appears to be a safe and effective treatment for benign prostatic enlargement, irrespective of the prostate size.